Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase

Autor: Catherine Chassagne-Clément, Philippe Rousselot, Isabelle Tigaud, Luigina Mollica, Françoise Berger, Michel Tulliez, Laurence Legros, Delphine Rea, Stéphane Giraudier, Ali G. Turhan, Clémence Roux, Mathilde Niault, Franck-Emmanuel Nicolini
Přispěvatelé: Institut de Biologie Valrose (IBV), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)
Jazyk: angličtina
Rok vydání: 2013
Předmět:
Dasatinib
MESH: Lymph Nodes
Biochemistry
Lymphoid hyperplasia
Tyrosine-kinase inhibitor
0302 clinical medicine
hemic and lymphatic diseases
MESH: Protein Kinase Inhibitors
Lymph node
[SDV.BDD]Life Sciences [q-bio]/Development Biology
ComputingMilieux_MISCELLANEOUS
MESH: Aged
0303 health sciences
music.instrument
MESH: Middle Aged
Drug Substitution
Myeloid leukemia
Hematology
Middle Aged
Follicular hyperplasia
3. Good health
Leukemia
medicine.anatomical_structure
030220 oncology & carcinogenesis
medicine.symptom
medicine.drug
Adult
medicine.drug_class
Immunology
MESH: Thiazoles
Antineoplastic Agents
MESH: Drug Administration Schedule
Drug Administration Schedule
03 medical and health sciences
Myelogenous
Leukemia
Myelogenous
Chronic
BCR-ABL Positive
medicine
Humans
music
Protein Kinase Inhibitors
Aged
030304 developmental biology
Hyperplasia
MESH: Humans
MESH: Hyperplasia
business.industry
MESH: Chronic Disease
MESH: Adult
Cell Biology
medicine.disease
MESH: Drug Substitution
Thiazoles
Pyrimidines
MESH: Karyotyping
MESH: Leukemia
Myelogenous
Chronic
BCR-ABL Positive
Karyotyping
MESH: Pyrimidines
Chronic Disease
Cancer research
MESH: Antineoplastic Agents
Lymph Nodes
business
Zdroj: Blood
Blood, American Society of Hematology, 2013, 122 (17), pp.3082-4. ⟨10.1182/blood-2013-07-513879⟩
ISSN: 0006-4971
1528-0020
DOI: 10.1182/blood-2013-07-513879⟩
Popis: To the editor: Dasatinib is a tyrosine kinase inhibitor licensed in the treatment of chronic myeloid leukemia (CML) known to exert immunomodulatory effects in vitro and in vivo.[1][1] We report on 9 chronic phase CML patients who developed follicular lymphoid hyperplasia (FLH) apparently caused by
Databáze: OpenAIRE
Externí odkaz: